Firefly Reveals EEG Biomarkers Distinguishing Three ADHD Subtypes; Targets $10B Market
Firefly Neuroscience’s FDA-510(k)-cleared Evoke System has identified novel EEG/ERP biomarkers that differentiate hyperactive/impulsive, inattentive and combined ADHD subtypes using AI analysis of over 191,000 brain scans. This capability could enable clinicians to tailor treatment types, dosages and monitor neural responses in the U.S. ADHD market valued at over $10 billion.
1. Discovery of EEG Biomarkers for ADHD Subtypes
Firefly announced that its AI-powered Evoke System has identified distinct brain wave signatures differentiating hyperactive/impulsive, inattentive and combined ADHD subtypes. This represents the first objective biological markers for subtype diagnosis.
2. Technology and Data Scale
The platform leverages Resting EEG and Cognitive EEG (ERP) scans from its FDA-510(k)-cleared Evoke System, training on a repository of over 191,000 standardized brain scans. GPU acceleration from NVIDIA underpins advanced signal processing and machine learning models.
3. Clinical Implications and Market Potential
Objective subtype identification could guide stimulant versus neurofeedback therapies, optimize dosages, and monitor treatment efficacy at the neural level. With the U.S. ADHD treatment market estimated at over $10 billion, the discovery could enhance personalized brain health solutions.
4. Strategic Outlook
Firefly aims to expand its foundation model to cover additional neurological and mental health conditions such as depression, dementia and anxiety disorders. Continued biomarker research and partnerships might drive future product development and commercial adoption.